r-n-jРоссийский неврологический журналRussian neurological journal2658-79472686-7192МИА10.30629/2658-7947-2024-29-2-17-23r-n-j-551Research ArticleОБЗОРЫREVIEWSСовременные аспекты профилактической фармакотерапии мигрениАctual aspects of migraines preventive pharmacotherapyhttps://orcid.org/0000-0003-0627-8372ГанцгорнЕ. В.GantsgornE. V.

Ростов-на-Дону

Rostov-on-Don

gantsgorn@inbox.ruhttps://orcid.org/0000-0003-4625-6186СафроненкоА. В.SafronenkoA. V.

Ростов-на-Дону

Rostov-on-Don

andrejsaf@mail.ruhttps://orcid.org/0000-0002-8886-8984ПоляковаВ. И.PolyakovaV. I.

Ростов-на-Дону

Rostov-on-Don

polyakova.vi@yandex.ruhttps://orcid.org/0000-0002-2143-4698МанвелянР. М.ManvelyanR. M.

Ростов-на-Дону

Rostov-on-Don

manvelyan.roland@mail.ruhttps://orcid.org/0000-0002-0596-5819АнтонянБ. Г.AntonyanB. G.

Ростов-на-Дону

Rostov-on-Don

boriska.antonyan@mail.ruhttps://orcid.org/0009-0001-8558-4855НиколаенкоА. В.NikolaenkoA. V.

Ростов-на-Дону

Rostov-on-Don

arina.nikolaenko1107@ya.ruhttps://orcid.org/0009-0007-5048-2174БалоянА. А.BaloyanA. A.

Ростов-на-Дону

Rostov-on-Don

baloyan_2020@list.ruhttps://orcid.org/0009-0009-5124-9563БохановГ. А.BokhanovG. A.

Ростов-на-Дону

Rostov-on-Don

roball966@gmail.comhttps://orcid.org/0009-0002-1287-8366НепокрытаяД. С.NepokrytayaD. S.

Ростов-на-Дону

Rostov-on-Don

dnepokrytaya@mail.ruhttps://orcid.org/0009-0008-5223-4139ИльинаА. А.IlyinaA. A.

Ростов-на-Дону

Rostov-on-Don

alisailina0706@gmail.comРостовский государственный медицинский университетРоссияRostov State Medical UniversityRussian Federation2024240520242921723Copyright © Ганцгорн Е.В., Сафроненко А.В., Полякова В.И., Манвелян Р.М., Антонян Б.Г., Николаенко А.В., Балоян А.А., Боханов Г.А., Непокрытая Д.С., Ильина А.А., 20242024Ганцгорн Е.В., Сафроненко А.В., Полякова В.И., Манвелян Р.М., Антонян Б.Г., Николаенко А.В., Балоян А.А., Боханов Г.А., Непокрытая Д.С., Ильина А.А.Gantsgorn E.V., Safronenko A.V., Polyakova V.I., Manvelyan R.M., Antonyan B.G., Nikolaenko A.V., Baloyan A.A., Bokhanov G.A., Nepokrytaya D.S., Ilyina A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.r-n-j.com/jour/article/view/551

Головные боли являются одной из наиболее распространенных причин нетрудоспособности во всем мире, при этом на первый план выходит мигрень. Новой и перспективной превентивной стратегией по борьбе с мигренью являются лекарственные средства из группы моноклональных антител к кальцитонин-ген-родственному пептиду. Высокая эффективность, хорошая переносимость, возможность повышения комплаентности пациентов увеличивают интерес специалистов к данным препаратам. Также большое значение имеют потенциально значимое снижение экономического бремени для общества и здравоохранения, существенное влияние на повышение качества жизни пациентов. Несмотря на перспективность применения обозначенных средств для профилактики мигренозных головных болей, не все аспекты, связанные с этим, на сегодняшний день рассмотрены и решены в полном объеме.

Headaches are one of the most common causes of disability worldwide, with migraines coming to the fore. A new and promising preventive strategy to combat migraine is drugs from the group of monoclonal antibodies to calcitonin-a gene-related peptide. High efficacy, good tolerability, and the ability to increase patient compliance increase the interest of specialists in these drugs. A potentially significant reduction in the economic burden on society and healthcare also plays an important role as a significant impact on improving the quality of life of patients. Despite the prospects of using these drugs for the prevention of migraine headaches, not all aspects related to this have been fully considered and resolved to date.

мигреньпрофилактикакальцитонин-ген-родственный пептидмоноклональные антителаmigrainepreventioncalcitonin gene-related peptidemonoclonal antibodiesReferencesВсемирная организация здравоохранения. Головные боли. 2016. URL: https://www.who.int/ru/news-room/fact-sheets/detail/headache-disordersWorld Health Organization. Headache disorders. 2016. (In Russ.). URL: https://www.who.int/ru/news-room/fact-sheets/detail/headache-disordersКлинические рекомендации «Мигрень». 2021, Минздрав РФ. URL: https://cr.minzdrav.gov.ru/schema/295_2Clinical recommendations “Migraine”. 2021, Ministry of Health of the Russian Federation. (In Russ.). URL: https://cr.minzdrav.gov.ru/schema/295_2Steiner T.J., Stovner L., Jensen R., Uluduz D., Katsarava Z. The burden: the global campaign against headache. Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019. The Journal of Headache and Pain. 2020;137:21. https://doi.org/10.1186/s10194-020-01208-0Steiner T.J., Stovner L., Jensen R., Uluduz D., Katsarava Z. The burden: the global campaign against headache. Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019. The Journal of Headache and Pain. 2020;137:21. https://doi.org/10.1186/s10194-020-01208-0Global, regional and national incidence, prevalence and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1545–1602. https://doi.org/10.1016/S0140-6736(16)31678-6Global, regional and national incidence, prevalence and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1545–1602. https://doi.org/10.1016/S0140-6736(16)31678-6Колбин А.С., Наприенко М.В., Артеменко А.Р., Вилюм И.А., Латышева Н.В., Проскурин М.А., Балыкина Ю.Е. Социально-экономическое бремя хронической мигрени в России. Качественная Клиническая Практика. 2018;(3):26–44. https://doi.org/10.24411/2588-0519-2018-10049Kolbin A.S., Naprienko M.V., Artemenko A.R., Vilyum I.A., Latysheva N.V., Proskurin M.A., Balykina Yu.Y. Socio-economic burden of chronic migraine in Russia. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2018;(3):26–44. (In Russ.). https://doi.org/10.24411/2588-0519-2018-10049Азимова Ю.Э., Амелин А.В., Алферова В.В., Артеменко А.Р., Ахмадеева Л.Р., Головачева В.А. и др. Клинические рекомендации «Мигрень». Журнал неврологии и психиатрии им. С.С. Корсакова. 2022;122(1–3):4–36. https://doi.org/10.17116/jnevro20221220134Azimova Y.E., Amelin A.V., Alferova V.V., Artemenko A.R., Akhmadeeva L.R., Golovacheva V.A. et al. Clinical guidelines «Migraine». Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2022;122(1-3):4-36. (In Russ.). https://doi.org/10.17116/jnevro20221220134Кондратьева Н.С., Анучина А.А., Кокаева З.Г., Наумова Е.А., Азимова Ю.Э., Сергеев А.В., и др. Генетика мигрени. Медицинская генетика. 2016;15(1):3–13. URL: https://www.medgen-journal.ru/jour/article/view/86Kondratieva N.S., Anuchina A.A., Kokaeva Z.G., Naumova E.A., Azimova J.E., Sergeev A.V. et al. Genetics of migraine. Medical Genetics. 2016;15(1):3–13. (In Russ.). URL: https://www.medgen-journal.ru/jour/article/view/86Глембоцкая Г.Т., Козуб О.В. Фармакоэкономическая оценка «бремени» мигрени в Российской Федерации. Клиническая фармакология и терапия. 2013;22(2):83–86. URL: https://www.elibrary.ru/item.asp?id=21229349Glembotskaya G.T., Kozub O.V. Farmakoekonomicheskaya otsenka «bremeni» migreni v Rossiiskoi Federatsii. Klinicheskaya Farmakologiya i Terapiya. 2013;22(2):83–86. (In Russ.). URL: https://www.elibrary.ru/item.asp?id=21229349Садоха К.А. Мигрень: настоящее и будущее. Медицинские новости. 2020;2:32–38. URL: https://cyberleninka.ru/article/n/migren-nastoyaschee-i-buduscheeSadokha K.A. Migraine: present and future. Meditsinskie novosti. 2020;2:32–38. (In Russ.). URL: https://cyberleninka.ru/article/n/migren-nastoyaschee-i-buduscheeБолдырева Ю.В., Лебедев И.А., Осанова П.С. Молекулярные механизмы возникновения мигрени. Модернизация науки и образования: современные реалии, пути совершенствования. Материалы XXXIV Всероссийской научно-практической конференции. Ростов-на-Дону, 2021:72–74. Издательство: ООО «Издательство ВВМ» (Санкт-Петербург) URL: https://elibrary.ru/download/elibrary_46424958_85348031.pdfBoldyreva YU.V., Lebedev I.A., Osanova P.S.. Molecular mechanisms of migraine. Modernization of science and education: modern realities, ways of improvement. Materials of the XXXIV All-Russian Scientific and Practical Conference (Modernizaciya nauki i obrazovaniya: sovremennye realii, puti sovershenstvovaniya. Materialy XXXIV Vserossijskoj nauchno-prakticheskoj konferencii. Rostov-on-Don, 2021:72–74. Publisher: VVM Publishing House LLC (St. Petersburg). (In Russ.). URL: https://elibrary.ru/download/elibrary_46424958_85348031.pdfHu X., Zhou Y., Zhao H., Peng C. Migraine and the risk of stroke: an updated meta-analysis of prospective cohort studies. Neurol Sci. 2017;38(1):33–40. https://doi.org/10.1007/s10072-016-2746-zHu X., Zhou Y., Zhao H., Peng C. Migraine and the risk of stroke: an updated meta-analysis of prospective cohort studies. Neurol Sci. 2017;38(1):33–40. https://doi.org/10.1007/s10072-016-2746-zTepper T.S., Rapoport A., Sheftell F. Mechanisms of action of the 5-HT1B/1D receptor agonists. Arch. Neurol. 2002;59(7):1084– 1088. https://doi.org/10.1001/archneur.59.7.1084Tepper T.S., Rapoport A., Sheftell F. Mechanisms of action of the 5-HT1B/1D receptor agonists. Arch. Neurol. 2002;59(7):1084– 1088. https://doi.org/10.1001/archneur.59.7.1084Yang Y.C., Liang C., Chang C., Yang C., Shih P., Yau Y. et al. Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine: A Systematic Review and Metaanalysis. JAMA Netw Open. 2021;4(10):e2128544. https://doi.org/10.1001/jamanetworkopen.2021.28544Yang Y.C., Liang C., Chang C., Yang C., Shih P., Yau Y. et al. Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine: A Systematic Review and Metaanalysis. JAMA Netw Open. 2021;4(10):e2128544. https://doi.org/10.1001/jamanetworkopen.2021.28544Marmura M. Triggers, protectors, and predictors in episodic migraine. Curr Pain Headache Rep. 2018;22(12):81. https://doi.org/10.1007/s11916-018-0734-0Marmura M. Triggers, protectors, and predictors in episodic migraine. Curr Pain Headache Rep. 2018;22(12):81. https://doi.org/10.1007/s11916-018-0734-0Shields S.K., Goadsby P. Propranolol modulates trigeminovascular responses in thalamic ventroposteromedial nucleus: a role in migraine? Brain. 2005;128:86–97. https://doi.org/10.1093/brain/awh298Shields S.K., Goadsby P. Propranolol modulates trigeminovascular responses in thalamic ventroposteromedial nucleus: a role in migraine? Brain. 2005;128:86–97. https://doi.org/10.1093/brain/awh298Jackson J., Kuriyama A., Kuwatsuka Y., Nickoloff S., Storch D., Jackson W. et al. Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis. PLoS One. 2019;14(3):e0212785. https://doi.org/10.1371/journal.pone.0212785Jackson J., Kuriyama A., Kuwatsuka Y., Nickoloff S., Storch D., Jackson W. et al. Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis. PLoS One. 2019;14(3):e0212785. https://doi.org/10.1371/journal.pone.0212785Becker B.W. Botulinum Toxin in the Treatment of Headache. Toxins (Basel). 2020;12(12):803. https://doi.org/110.3390/toxins12120803Becker B.W. Botulinum Toxin in the Treatment of Headache. Toxins (Basel). 2020;12(12):803. https://doi.org/110.3390/toxins12120803Silberstein S., Holland S., Freitag F., Dodick D.W., Argoff C., Ashman E. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78(17):1337–1345. https://doi.org/10.1212/WNL.0b013e3182535d20Silberstein S., Holland S., Freitag F., Dodick D.W., Argoff C., Ashman E. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78(17):1337–1345. https://doi.org/10.1212/WNL.0b013e3182535d20Сорокина Н.Д., Перцов С.С., Селицкий Г.В., Жердева А.С. Противоэпилептические препараты в лечении мигрени и невропатической боли. Российский журнал боли. 2021;19(3):45–52. https://doi.org/10.17116/pain20211903145Sorokina N.D., Pertsov S.S., Selitsky G.V., Zherdeva A.S. Antiepileptic drugs in the treatment of migraine and neuropathic pain. Russian journal of pain. 2021;19(3):45–52. (In Russ.). https://doi.org/10.17116/pain20211903145Schneider S.J., Patterson M., Jimenez X. Beyond depression: Other uses for tricyclic antidepressants. Cleve Clin. J. Med. 2019;86(12):807–814. https://doi.org/10.3949/ccjm.86a.19005Schneider S.J., Patterson M., Jimenez X. Beyond depression: Other uses for tricyclic antidepressants. Cleve Clin. J. Med. 2019;86(12):807–814. https://doi.org/10.3949/ccjm.86a.19005Азимова Ю.Э., Ашихмин Я.И., Кукушкин М.Л., Моноклональные антитела к CGRP: новое слово в лечении мигрени. Российский журнал боли. 2019;17(2):61–66. https://doi.org/10.25731/RASP.2019.02.22Azimova J.E., Ashikhmin Ya.I., Kukushkin M.L. Monoclonal antibodies to CGRP: a new word in the treatment of migraine. Russian Journal of Pain. 2019;17(2):61–66. (In Russ.). https://doi.org/10.25731/RASP.2019.02.22Vandervorst V.F., Van Deun L., Van Dycke A., Paemeleire K., Reuter U., Schoenen J., Versijpt J. CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs. The journal of headache and pain. 2021;22(1):128. https://doi.org/10.1186/s10194-021-01335-2Vandervorst V.F., Van Deun L., Van Dycke A., Paemeleire K., Reuter U., Schoenen J., Versijpt J. CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs. The journal of headache and pain. 2021;22(1):128. https://doi.org/10.1186/s10194-021-01335-2Dodick D., Doty E., Aurora S., Ruff D., Stauffer V., Jedynak J. et al. Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine. Cephalalgia. 2021;41(3):340–352. https://doi.org/10.1177/0333102420966658Dodick D., Doty E., Aurora S., Ruff D., Stauffer V., Jedynak J. et al. Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine. Cephalalgia. 2021;41(3):340–352. https://doi.org/10.1177/0333102420966658Goadsby G.P., Reuter U., Hallström Y., Broessner G., Bonner J.H., Zhang F. et al. A controlled trial of erenumab for episodic migraine. N. Engl. J. Med. 2017;377(22):2123–2132. https://doi.org/10.1056/NEJMoa1705848Goadsby G.P., Reuter U., Hallström Y., Broessner G., Bonner J.H., Zhang F. et al. A controlled trial of erenumab for episodic migraine. N. Engl. J. Med. 2017;377(22):2123–2132. https://doi.org/10.1056/NEJMoa1705848Екушева Е.В., Артеменко А.Р., Ширшова Е.В., Соков П.Е., Плиева А.М. Применение Эренумаба у пациентов с хронической мигренью в реальной клинической практике. Российский неврологический журнал. 2021;26(5):44–50. https://doi.org/10.30629/2658-7947-2021-26-5-44-50Ekusheva E.V., Artemenko A.R., Shirshova E.V., Sokov P.E., Plieva A.M. The use of the monoclonal antibody Erenumab in patients with chronic migraine in real clinical experience. Russian Neurological Journal (Rossijskij Nevrologicheskiy Zhurnal). 2021;26(5):44–50. (In Russ.). https://doi.org/10.30629/2658-7947-2021-26-5-44-50Saper S.J., Lipton R., Kudrow D., Hirman J., Dodick D., Silberstein S. et al. A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of eptinezumab in frequent episodic migraine prevention: primary results of the PROMISE 1 (PRevention Of Migraine via Intravenous eptinezumab: Safety and Efficacy 1) Trial. Cephalalgia. 2017;37:33. https://scholar.google.com/citations?view_op=view_citation&hl=en&user=ymK9SakAAAAJ&citation_for_view=ymK9SakAAAAJ:YOwf2qJgpHMCSaper S.J., Lipton R., Kudrow D., Hirman J., Dodick D., Silberstein S. et al. A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of eptinezumab in frequent episodic migraine prevention: primary results of the PROMISE 1 (PRevention Of Migraine via Intravenous eptinezumab: Safety and Efficacy 1) Trial. Cephalalgia. 2017;37:33. https://scholar.google.com/citations?view_op=view_citation&hl=en&user=ymK9SakAAAAJ&citation_for_view=ymK9SakAAAAJ:YOwf2qJgpHMCDodick D.W., Silberstein S.D., Bigal M.E., Yeung P.P., Goadsby P.J., Blankenbiller T. et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine. JAMA. 2018;319(19):1999–2008. https://doi.org/10.1001/jama.2018.4853Dodick D.W., Silberstein S.D., Bigal M.E., Yeung P.P., Goadsby P.J., Blankenbiller T. et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine. JAMA. 2018;319(19):1999–2008. https://doi.org/10.1001/jama.2018.4853Lampl L.C., MaassenVanDenBrink A., Deligianni C., Gil-Gouveia R., Jassal T., Sanchez-Del-Rio M. et al. The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis. J. Headache Pain. 2023;24(1):56. https://doi.org/10.1186/s10194-023-01594-1Lampl L.C., MaassenVanDenBrink A., Deligianni C., Gil-Gouveia R., Jassal T., Sanchez-Del-Rio M. et al. The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis. J. Headache Pain. 2023;24(1):56. https://doi.org/10.1186/s10194-023-01594-1Сафроненко А.В., Ганцгорн Е.В., Постникова Е.С., Полякова В.И., Манвелян Р.М., Антонян Б.Г. и др. Применение фреманезумаба для профилактики обострений хронической мигрени (клинический случай). Экспериментальная и клиническая фармакология. 2023;86(8):9–14. https://doi.org/10.30906/0869-2092-2023-86-8-9-14Safronenko A.V., Gantsgorn E.V., Postnikova E.S., Polyakova V.I., Manvelyan R.M., Antonyan B.G. et al. Usage of fremanezumab for the prevention of exacerbations of chronic migraine: clinical case. Experimental and clinical pharmacology. 2023;86(8):9–14. (In Russ.). https://doi.org/10.30906/0869-2092-2023-86-8-9-14Camporeale A., Kudrow D., Sides R., Wang S., Dycke A.V., Selzler K.J., Stauffer V.L. A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine. BMC Neurology. 2018;188(18). https://doi.org/10.1186/s12883-018-1193-2Camporeale A., Kudrow D., Sides R., Wang S., Dycke A.V., Selzler K.J., Stauffer V.L. A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine. BMC Neurology. 2018;188(18). https://doi.org/10.1186/s12883-018-1193-2Sacco S., Amin F., Ashin M., Bendtsen L., Deligianni C.I., Gil-Gouveia R. et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention — 2022 update. J. Headache Pain. 2022;23:67. https://doi.org/10.1186/s10194-022-01431-xSacco S., Amin F., Ashin M., Bendtsen L., Deligianni C.I., Gil-Gouveia R. et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention — 2022 update. J. Headache Pain. 2022;23:67. https://doi.org/10.1186/s10194-022-01431-xDodick D., Lipton R., Silberstein S., Goadsby P., Biondi D., Hirman J. et al. Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial. Cephalalgia. 2019;39(9):1075– 1085. https://doi.org/10.1177/0333102419858355Dodick D., Lipton R., Silberstein S., Goadsby P., Biondi D., Hirman J. et al. Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial. Cephalalgia. 2019;39(9):1075– 1085. https://doi.org/10.1177/0333102419858355Detke H.C., Goadsby P.J., Wang S., Friedman D.I., Selzler K.J., Aurora S.K. Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211–e2221. https://doi.org/10.1212/WNL.0000000000006640Detke H.C., Goadsby P.J., Wang S., Friedman D.I., Selzler K.J., Aurora S.K. Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211–e2221. https://doi.org/10.1212/WNL.0000000000006640Silberstein S., Dodick D., Bigal M., Yeung P.P, Goadsby P.J, Blankenbiller T. et al. Fremanezumab for the preventive treatment of chronic migraine. N. Engl. J. Med. 2017;377:2113–2122. https://doi.org/10.1056/NEJMoa1709038Silberstein S., Dodick D., Bigal M., Yeung P.P, Goadsby P.J, Blankenbiller T. et al. Fremanezumab for the preventive treatment of chronic migraine. N. Engl. J. Med. 2017;377:2113–2122. https://doi.org/10.1056/NEJMoa1709038Diener H.C., Marmura M.J., Tepper S.J., Cowan R., Starling A.J., Diamond M.L. et al. Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2. Headache. 2021;61(1):125–136. https://doi.org/10.1111/head.14036Diener H.C., Marmura M.J., Tepper S.J., Cowan R., Starling A.J., Diamond M.L. et al. Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2. Headache. 2021;61(1):125–136. https://doi.org/10.1111/head.14036Silberstein S., Cohen J., Seminerio M., Yang R., Ashina S., Katsarava Z. The impact of fremanezumab on medication over-use in patients with chronic migraine: subgroup analysis of the HALO CM study. J. Headache Pain. 2020;21(1):114. https://doi.org/10.1186/s10194-020-01173-8Silberstein S., Cohen J., Seminerio M., Yang R., Ashina S., Katsarava Z. The impact of fremanezumab on medication over-use in patients with chronic migraine: subgroup analysis of the HALO CM study. J. Headache Pain. 2020;21(1):114. https://doi.org/10.1186/s10194-020-01173-8Sprenger S.T., Viana M., Tassorelli C. Current prophylactic medications for migraine and their potential mechanisms of action. Neurotherapeutics. 2018;15:313–323. https://doi.org/10.1007/s13311-018-0621-8Sprenger S.T., Viana M., Tassorelli C. Current prophylactic medications for migraine and their potential mechanisms of action. Neurotherapeutics. 2018;15:313–323. https://doi.org/10.1007/s13311-018-0621-8Pham P.A., Burch R. Headache. 2020;60:4–5. https://headache-journal.onlinelibrary.wiley.com/toc/15264610/2020/60/5Pham P.A., Burch R. Headache. 2020;60:4–5. https://headache-journal.onlinelibrary.wiley.com/toc/15264610/2020/60/5Ornello O.R., Baraldi C., Guerzoni S., Lambru G., Andreou A.P., Raffaelli B. et al. Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study. J. Headache Pain. 2022;23(1):38. https://doi.org/10.1186/s10194-022-01408-wOrnello O.R., Baraldi C., Guerzoni S., Lambru G., Andreou A.P., Raffaelli B. et al. Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study. J. Headache Pain. 2022;23(1):38. https://doi.org/10.1186/s10194-022-01408-wSacco S., Lampl C., MaassenVanDenBrink A., Caponnetto V., Braschinsky M., Ducros A. et al. Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance. J. Headache Pain. 2021;22(1):39. https://doi.org/10.1186/s10194-021-01252-4Sacco S., Lampl C., MaassenVanDenBrink A., Caponnetto V., Braschinsky M., Ducros A. et al. Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance. J. Headache Pain. 2021;22(1):39. https://doi.org/10.1186/s10194-021-01252-4Restituto R.D., Fabo E., Bujanda M. Salvage therapy for patients who do not respond to the first anti-CGRP monoclonal antibody: a new chance for patients with migraine? Neurology Perspectives. 2022;2(2):102–104. https://doi.org/10.1016/j.neurop.2021.11.009Restituto R.D., Fabo E., Bujanda M. Salvage therapy for patients who do not respond to the first anti-CGRP monoclonal antibody: a new chance for patients with migraine? Neurology Perspectives. 2022;2(2):102–104. https://doi.org/10.1016/j.neurop.2021.11.009Argyriou A.A., Dermitzakis E.V., Xiromerisiou G., Vikelis M. On a botulinum toxin A add-on to monoclonal anti-CGRP antibodies in treatment-refractory chronic migraine. Toxins. 2022;14(12):847. https://doi.org/10.3390/toxins14120847Argyriou A.A., Dermitzakis E.V., Xiromerisiou G., Vikelis M. On a botulinum toxin A add-on to monoclonal anti-CGRP antibodies in treatment-refractory chronic migraine. Toxins. 2022;14(12):847. https://doi.org/10.3390/toxins14120847Goadsby G.P., Silberstein S., Yeung P., Cohen J.M., Ning X., Yang R., Dodick D.W. Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized study. Neurology. 2020;95(18):e2487-e2499. https://doi.org/10.1212/WNL.0000000000010600Goadsby G.P., Silberstein S., Yeung P., Cohen J.M., Ning X., Yang R., Dodick D.W. Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized study. Neurology. 2020;95(18):e2487-e2499. https://doi.org/10.1212/WNL.0000000000010600Depre C., Antalik L., Starling A., Koren M., Eisele O., Lenz R.A., Mikol D.D. A randomized, double-blind, placebo-controlled study to evaluate the effect of erenumab on exercise time during a treadmill test in patients with stable angina. Headache. 2018;58(5):715-723. https://doi.org/10.1111/head.13316Depre C., Antalik L., Starling A., Koren M., Eisele O., Lenz R.A., Mikol D.D. A randomized, double-blind, placebo-controlled study to evaluate the effect of erenumab on exercise time during a treadmill test in patients with stable angina. Headache. 2018;58(5):715-723. https://doi.org/10.1111/head.13316Bussiere J., Davies R., Dean C., Xu C., Kim K.H., Vargas H.M. et al. Nonclinical safety evaluation of erenumab, a GGRP receptor for the prevention of migraine. Regulatory Toxicology and Pharmacology. 2019;106:224–238. https://doi.org/10.1016/j.yrtph.2019.05.013Bussiere J., Davies R., Dean C., Xu C., Kim K.H., Vargas H.M. et al. Nonclinical safety evaluation of erenumab, a GGRP receptor for the prevention of migraine. Regulatory Toxicology and Pharmacology. 2019;106:224–238. https://doi.org/10.1016/j.yrtph.2019.05.013Yadav S., Yadav Y.S., Goel M.M., Singh U., Natu S.M., Singh Negi M.P. Calcitonin gene- and parathyroid hormone-related peptides in normotensive and preeclamptic pregnancies: a nested case–control study. Arch Gynecol Obstet. 2014;290(5):897–903. https://doi.org/10.1007/s00404-014-3303-8Yadav S., Yadav Y.S., Goel M.M., Singh U., Natu S.M., Singh Negi M.P. Calcitonin gene- and parathyroid hormone-related peptides in normotensive and preeclamptic pregnancies: a nested case–control study. Arch Gynecol Obstet. 2014;290(5):897–903. https://doi.org/10.1007/s00404-014-3303-8Al-Hassany L., Goadsby P.J., Danser A.J., Maassen Van Den Brank A. С. Lancet Neurol. 2022;21(3):284–294. https://doi.org/10.1016/S1474-4422(21)00409-9Al-Hassany L., Goadsby P.J., Danser A.J., Maassen Van Den Brank A. С. Lancet Neurol. 2022;21(3):284–294. https://doi.org/10.1016/S1474-4422(21)00409-9

The authors declare that there are no conflicts of interest present.